Back to mobile site

Firefly and NeuroSigma partner to expand pediatric ADHD treatment

September 25, 2026 7:45 AM EDT

Firefly Neuroscience (NASDAQ: AIFF) and NeuroSigma announced a partnership to distribute NeuroSigma's Monarch eTNS® System through Firefly's nationwide network of Evoke™ clinicians, according to a press release dated Sept. 25, 2026.

The Monarch eTNS® System is the first non-drug treatment for pediatric attention-deficit/hyperactivity disorder cleared by the U.S. Food and Drug Administration. The prescription-only device delivers mild external trigeminal nerve stimulation through an adhesive patch placed on a child's forehead during sleep. It is cleared as a monotherapy for children ages 7 through 12 who are not currently taking prescription ADHD medication.

NeuroSigma began U.S. sales of its second-generation Monarch device in July 2026, following the development of a waitlist of more than 1,500 patients, caregivers, and healthcare providers. In September 2026, the company expanded payment options to include third-party installment plans.

Under the agreement, Firefly will introduce the Monarch device to psychiatry, neurology, and behavioral health practices that use its FDA 510(k)-cleared Evoke™ EEG/ERP platform. NeuroSigma will provide clinical training, prescribing support, and product fulfillment through a specialty pharmacy partner.

Firefly's Evoke™ platform uses quantitative electroencephalography and event-related potential testing with AI-powered analytics, drawing on a database the company states contains more than 200,000 EEG/ERP brain scans.

A 2024 study published in the Journal of Clinical Child & Adolescent Psychology estimated that approximately 7.1 million U.S. children have received an ADHD diagnosis, with nearly one-third of those with current ADHD receiving no ADHD-specific treatment.

"By introducing NeuroSigma's FDA-cleared, non-drug therapy to our Evoke clinician network, we are connecting measurement-driven practices with an important treatment option for eligible children and their families," said Greg Lipschitz, Chief Executive Officer of Firefly.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Hot Corp. News

Related Entities

Maynard Um, Mark Zuckerberg, FDA, ARK